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doi:10.101Cellular Immune Reconstitution and Its Impact on
Clinical Outcome in Children with b Thalassemia Major
Undergoing a Matched Related Myeloablative
Allogeneic Bone Marrow Transplant
Reena Rajasekar, Vikram Mathews, Kavitha M. Lakshmi, Biju George, Auro Viswabandya,
Mammen Chandy, Alok SrivastavaWe have prospectively analyzed cellular immune reconstitution (IR) in 63 consecutive pediatric patients with
b thalassemia major who underwent an HLA matched related allogeneic bone marrow transplant (BMT).
Samples from bone marrow graft and posttransplant peripheral blood samples from recipients at specified
time points were assessed for IR of cellular subsets. The median age of the cohort was 7 years, and there
were 37 (59%) males. A CD34 cell dose above the median value of 7.3  106/kg had a lower incidence of
bacterial (P 5 .003) and fungal (P 5 .003) infections in the posttransplant period, and was not associated
with an increased risk of graft-versus-host disease (GVHD). Among cases that did develop grade II-IV
GVHD the absolute CD8 (116 versus 52 cells/mL, P 5 .012), CD8 naı¨ve (74 versus 9 cells/mL, P 5 .005),
and CD8memory counts (44 versus 21 cells/mL, P5.010) were significantly higher on day 15. Fifteen patients
(24%) rejected their graft (7 primary and 8 secondary). The day 28 natural killer (NK) cell count was signif-
icantly associated with secondary graft rejection, event-free survival (EFS), and overall survival (OS) (P 5
.044, .013, and .034, respectively). On a multivariate analysis, patients with a day 28 NK cell count below
the median value of 142/mL had a significantly higher rejection rate (hazard ratio [HR] 5 11.1, P 5 .038)
and a lower EFS (HR 5 16.3, P 5 .034).
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An allogeneic stem cell transplant (SCT) remains
the only curative option for numerous malignant and
inherited hematologic conditions. The clinical efficacy
of an SCT is limited by regimen-related toxicity sec-
ondary to the conditioning regimen, immune response
by donor cells to recipient antigens resulting in graft
versus host disease (GVHD) and delayed or inade-
quate immune reconstitution leading to infections, re-
currence of a malignancy, and occasionally rejection of
the graft [1,2].Department of Haematology, Christian Medical College,
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6/j.bbmt.2009.01.016Although immune reconstitution post-SCT has
been extensively studied in adults, there is limited
data in the pediatric population [1]. An early low plas-
macytoid dendritic cell count has been reported by us
and others to be associated with acute and chronic
GVHD (aGVHD, cGVHD) [3,4]. Rapid lymphocyte
and lymphocyte subset recovery have been reported
to be associated with a favorable outcome [5-7]. It is
known that the ability to generate CD41CD45RA1
(naı¨ve T helper cells) decreases with age, because this
is thymic dependent [8,9]. It is also recognized that
there is earlier generation of helper T cells and B cells
in children than in adults [1]. There is, however, lim-
ited data on the impact of these variations in the pat-
tern of immune reconstitution on clinical outcomes
post-SCT in a uniform cohort of children.
Natural killer (NK) cells are innate immune cells
critical to host defense against invading pathogens
and malignant transformation. NK cells have been ex-
tensively studied in the posttransplant period, as they
are potentially associated with both rejection and
a graft-versus-leukemia (GVL) effect [10,11]. Experi-
mental data suggests that they have a number of597
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versus-leukemia effect reducing relapse, NK cell-
versus-residual host T cell reducing graft rejection
rate, and NK cell-versus-host dendritic cells, poten-
tially reducing the risk of GVHD [10,12,13]. In the
pediatric population with high-risk thalassemia major,
graft rejection is a major problem, and can occur in
20% to 50% of cases [14]. The impact of the pattern
of NK cell reconstitution in this population has not
been studied.
We prospectively analyzed the effect of immune
reconstitution in a pediatric population of patients
with b thalassemia major undergoing a myeloablative
HLA matched related allogeneic SCT.PATIENTS, MATERIALS, AND METHODS
This prospective study included all consecutive pa-
tients who underwent an allogeneic HLA matched re-
lated SCT for b thalassemia major at our center,
between December 2003 and December 2006. All pa-
tients had 6 antigen HLA-matched sibling or family
donors. A written informed consent was obtained
from parents or legal guardians for all patients.
Pretransplant Evaluation
All patients were evaluated with a complete blood
count (CBC), biochemical profile, and serology for hu-
man immunodeficienty virus (HIV), hepatitus B virus
(HBV), hepatitus C virus (HCV), and cytomegalovirus
(CMV). A liver biopsy was performed at the time of
Hickman catheter insertion.
Conditioning
Patients were conditioned using a conventional
myeloablative regimen consisting of busulfan (Bu)
from 16 mg/kg (1 mg/kg/dose 4 times daily  4
days) administered orally (dose adjustment based on
pharmacokinetic levels was not attempted), cyclo-
phopsphamide (Cy) 200 mg/kg given over 4 days (50
mg/kg/day i.v over 1 hour), and antilymphocyte glob-
ulin (PasteurMerieux, Lyon, France) or antithymocyte
globulin (ATG; Pharmacia and Upjohn, Kalamazoo,
MI) 30 mg/kg/day for 3 days as previously reported
[15]. In 25 patients, a newpreparative regimen of fludar-
abine (Flu; 150 mg/m2 over 5 days), Bu (14-16 mg/kg
over 4 days), and Cy (160 mg/kg over 4 days) was used.
Graft Source and Engraftment
The stem cell source was bone marrow (BM) for all
except 2 cases. BM was harvested under general anes-
thesia from the iliac crest and the target cell dose was 3
 108 nucleated cells/kg body weight of the recipient.
Unprimed BM was used in majority of the patients
(59%). Twenty-four (38%) patients received granulo-cyte colony stimulating factor (G-CSF) primed BM
(G-CSF 10 mg/kg/day  2 days prior to BM harvest).
GVHD Prophylaxis
Cyclosporine (CsA) and a short course of metho-
trexate (MTX) was used as GVHD prophylaxis; CsA
was administered at a dose of 2.5 mg/kg i.v. over
4 hours twice daily starting on day –4 and changed to
oral administration at 5 mg/kg twice daily whenmuco-
sitis had resolved. CsA levels were monitored and
the dose adjusted to achieve a target level of 100-400
ng/mL. CsA was administered for 6 months, and
over the next 6 months the dose was gradually tapered
and stopped. If there was active GVHD, tapering and
continuation of GVHD CsA beyond this period was
left to the treating physician’s discretion. The MTX
dose was 10 mg/m2 on day 21 and 7 mg/m2 on days
3, 6, and 11. If mucositis was severe (grade IV) or
bilirubin .20 mg/L, the day 6 and day 11 doses were
omitted.
Supportive Care
All patients were nursed in a positive pressure
HEPA-filtered transplant unit. Prophylactic acyclovir
was administered for the first 100 days; it was contin-
ued beyond day 100 if patient had GVHD and re-
quired additional immunosuppression. Quantitative
CMV polymerase chain reaction (PCR) analysis was
done from day 30 onward, once in 2 weeks up to day
100, more frequently if there was evidence of CMV
reactivation. Trimethoprim-sulphamethoxazole and
oral penicillin prophylaxis was initiated after stable
engraftment and continued for a year.
Flow Cytometric Analysis
Harvest samples from donors and peripheral blood
samples from posttransplant recipients were assessed
for stem cells, lymphocyte subsets, and dendritic cells
subsets. Posttransplant peripheral blood samples
were obtained from patients on day 15, day 28, day
45, 2 months, 3 months, 6 months, 9 months, and 12
months for flow cytometry analysis. Briefly, cells
were labeled using a panel of monoclonal antibodies
(mAbs) to CD34, CD133, CD3, CD4, CD45RA,
CD45RO, CD8, CD25, CD69, CD19, CD56,
CD16, CD11c, CD123, HLA-DR, and lineage cock-
tail antibodies directly conjugated with either fluores-
cein isothiocyanate (FITC), phycoerythrin (PE) or
peridinin chlorophyll protein (PerCP) (Becton Dick-
inson, San Jose, CA), followed by red cell lysis with
ammonium chloride. The cells were then washed and
analyzed using FACSCalibur (Becton Dickenson,
Mansfield, MA). Data analysis was performed using
CellQuestPro software (Becton Dickenson). Dead
cells were gated out before the final analysis using for-
ward versus side-scatter dot-plots. Lymphocyte subset
Biol Blood Marrow Transplant 15:597-609, 2009 599Cellular IR on Children with b Thalassemia Majorpercentages were calculated from the lymphocyte gate
as appropriate. The absolute lymphocyte subset counts
were then calculated from a routine automated leuko-
cyte count (Beckmann Coulter LH 750, Fullerton,
CA). A previously described method for identification
and enumeration of dendritic cell subsets was used
[16]. For stem cell enumeration (CD34) in the graft,
ISHAGE gating strategy was performed as described
previously [17].Definitions and Definition of Outcomes
Incidence and severity of GVHD was defined as
per established criteria [18]. Time to engraftment
for neutrophils was defined as the first of 3 consecutive
days on which absolute neutrophil count (ANC) was
.500/mm3. Time to engraftment for platelets was de-
fined as the first of 3 consecutive days on which the
unsupported platelet count was .20,000/mm3. Pri-
mary graft failure was defined by lack of neutrophil
engraftment (ANC \0.5  109/L) measured for 3
consecutive days by 28 days posttransplant. Secondary
graft rejection was defined when initial engraftment
was followed by subsequent development of ANC
\0.5  109/L for 3 consecutive measurements, recur-
rence of transfusion dependence, or pancytopenia
with a hypocellular marrow [19]. Secondary graft re-
jection was further defined as early (graft rejection
within 60 days after initial engraftment) or late (graft
rejection occurring after 60 days from SCT and initial
engraftment).
The data from pretransplant counts were used as
reference range for each of cellular subsets analyzed.
Achievement of the median pretransplant cellular sub-
set value was considered an event on a Kaplan-Meier
analysis. Patients who died before engraftment or had
a graft rejection after transplantation were censored
at that time point for immune reconstitution studies.
Conventional Lucarelli risk stratification for pa-
tients with b thalassemia major undergoing an alloge-
neic SCT was used [20]; additionally, a high-risk
subset of class III cases as previously described was
also utilized for analysis [21]. Event-free survival
(EFS) was defined from the time of transplant to an
event; an event was primary graft failure, death, or re-
currence of transfusion dependence. Stable mixed chi-
merism with transfusion independence was not
considered an event for this analysis. Overall survival
(OS) was defined as the time from transplant to death
from any cause.
Bacterial infection was defined as positive culture
from blood and any other sites (urine, sputum, pus,
abscess, and catheter). Bacterial pneumonia was also
diagnosed when there were clinical and radiologic
signs of pneumonia with or without positive sputum
culture or a pneumonia that improved after antibacte-
rial therapy [22]. CMV infection was defined as 2consecutive positive PCR assays within 1 week or
a CMV copy number .140 copies/mL whole blood
performed using artus CMV PCR Kits (Qiagen, Hil-
den, Germany). CMV disease was defined as the dem-
onstration of CMV by biopsy specimen from visceral
sites (by culture or histology) or the detection of
CMV by culture in broncho-alveolar fluid in the pres-
ence of new or changing pulmonary infiltrates [23]. All
fungal infections were documented as probable, possi-
ble, and proved fungal infections based upon the CDC
criteria [24].Statistical Analysis
For comparison of dichotomous variables, a c2 test
was done while continuous variables were compared
using either a Student’s t-test or a Mann-Whitney U-
test as was deemed appropriate. The probability of
survival was estimated using Kaplan-Meier method
for rejection, EFS, and OS, and compared by the
log-rank test. Cox models were used to assess the pro-
portional hazards of various subsets both in the graft
and those engrafted after transplant on clinical out-
comes such as rejection, GVHD, day 100 treatment-
related mortality (TRM), EFS, and OS. To confirm
outcomes and to adjust for potential confounding fac-
tors, multivariate Cox proportional hazards models
were also performed. Kinetics of lymphocyte recovery
was also evaluated by calculating area under curve
(AUC) using trapezoidal method [25]. For all the tests,
a value of P\ .05 was considered statistically signifi-
cant. Statistical analyses were performed using SPSS
for Windows 11.01 version (SPSS Inc., Chicago, IL).RESULTS
Demographic and Baseline Characteristics
A total of 63 patients with b thalassemia major un-
derwent an SCT between December 2003 and De-
cember 2006 at our center. The median age of this
cohort was 7 years (range: 2-14 years). There were
37 (59%)males and 25 (41%) females. By conventional
risk stratification [20], there were 7 (11%), 25 (40%),
and 31 (49%) transplants in class I, II, and III, respec-
tively. The baseline patient and graft characteristics
are summarized in Table 1. The median pretransplant
value of the total count and all the subsets analyzed ex-
cept for dendritic cell count was significantly lower
than agematched donors and that of age-matched chil-
dren as reported previously (supplementary data)
[26,27]. Achievement of the median pretransplant cel-
lular subset value was considered an event on a Kaplan-
Meier analysis. Patients who died before engraftment
or had a graft rejection after transplantation were cen-
sored at that time point for immune reconstitution
studies.
Table 1. Baseline Patient and Graft Characteristics
Characteristics n (%)/Median (Range)
Patient —
Age (years) 7 (2-14)
Males 37 (59)
Donor —
Age (years) 8 (2-39)
Males 27 (43)
Sex mismatch transplant 40 (64)
Lucarelli class III 31 (49)
Splenectomy 2 (3)
High risk (age $7 years and liver
size $5 cm) [21]
6 (10)
TNC (108/kg) 4.4 (1.7-22.7)
Conditioning regimen —
Bu/Cy/ATG 33 (52)
Bu/Cy/ALG 4 (6)
Bu/Cy 1 (1)
Flu/Bu/Cy 25 (39)
GVHD Prophylaxis —
CSA + MTX 62 (98)
CSA + Methlyprednisolone 1 (2)
Graft source BM 5 37; GBM 5 24; PBSC 5 2
Bu indicates Busulfan; ATGAM, antithymocyte globulin (Pharmacia Up-
john); ALG, antilymphocyte globulin (Pasteur Merieux); Cy, Cyclophos-
phamide; Flu, Fludarabine; CSA, Cyclosporine; MTX, Methotrexate; BM,
bone marrow; PBSC, peripheral blood stem cells.
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1.7-22.7) total nucleated cells/kg and 7.3  106
CD34/kg (range: 1.2-23). The total WBC count in
the harvested product was higher in G-CSF primed
BM (BM 5 19.7  109/L vs. G-BM 5 37.75  109/
L, P 5 .000), resulting in a lower volume of marrow
harvested to achieve the target cell dose of 3 108 total
nucleated cells/kg (BM5 430 mL versus G-BM5 280
mL, P5 .000). The graft characteristics were similar in
both BM and G-CSF-primed BM sources for stem cell
content (CD34, CD133), but significantly differed in
NK, CD19, CD8CD45RA, and plasmacytoid den-
dritic cell content (Table 2).
Clinical Outcomes
Of the 63 transplants, 2 patients had peritransplant
deaths related to regimen-related toxicity (RRT).
Among the 61 patients who could be evaluated for en-
graftment, 54 (89%) achieved sustained engraftment.
Seven patients (11%) had primary graft failure. Five
of these patients died prior to day 28 (time point for
the first chimerism analysis). Two patients’ had autol-
ogous reconstitution by day 20, and chimerism analy-
sis on day 28 revealed a complete absence of a donor
band; both are transfusion dependent and have re-
mained alive on follow-up for more than a year. Of
the 54 who had achieved sustained engraftment, 2
(4%) had early (.28 days and\60 days posttransplant)
and 6 (11%) had late secondary graft rejections (.60
days posttransplant). On day 28, the time point when
the first chimerism analysis was done, 7 of these pa-
tients had a mixed chimerism pattern with a median
donor band of 79% (range: 26-91), whereas 1 patienthad documented complete chimerism (100% donor
band) at this time point. The median time to graft re-
jection among these patients was 77 days (range: 53-
184 days).
Among the 54 who had engrafted, 2 died, 1 each on
day 17 and day 23 secondary to RRT complicated by
infections (prior to documentation of chimerism sta-
tus). Of the remaining 52 patients who could be evalu-
ated for aGVHD, 8 (15%) developed aGVHD grade
(II-IV), whereas 5 of 45 (11%) patients surviving
.100 days developed cGVHD. The Kaplan-Meier
3-year EFS and OS for the entire cohort was 67% 6
6% and 78% 6 5%, respectively, at a mean follow-
up of 37 months. The EFS and OS according to risk
stratification was, class I: 86% 6 13% and 86% 6
13%; class II: 75% 6 9% and 83% 6 8%; class III:
57% 6 9% and 66% 6 10%, respectively.Immune Reconstitution Post-SCT
The data from pretransplant counts were used as
reference ranges for each of the cellular subsets ana-
lyzed. Achievement of the median pretransplant
cellular subset value was considered an event on a
Kaplan-Meier analysis. NK cells were the first cells
to recover, within a month, in the early posttransplant
period. Following immune reconstitution of NK cells,
there was a transient increase in NK cell numbers
above pretransplant baseline levels, and thereafter re-
mained within the normal range throughout the rest
of the posttransplant period (Figure 1). Dendritic cells
(monocytoid and plasmacytoid) also recovered by day
30 posttransplant and thereafter remained within the
normal range. The Kaplan-Meier estimate of the
mean time for CD3 recovery is 9.7 months (95% con-
fidence interval [CI]: 8.5-12). Recovery of CD4 cells to
baseline levels is even further delayed with the mean
Kaplan-Meier estimate not being achieved in the 1
year study period of this analysis. At the end of 1
year, IR analysis revealed that only 7 of 54 (13%) pa-
tients who had sustained engraftment achieved the
pretransplant median CD4 levels. However, CD8 cells
reconstitute fairly rapidly with a median Kaplan-Meier
estimate of 2 months (95% CI: 0-4 months) resulting
in an inverted CD4/CD8 ratio for a prolonged period
following transplantation. CD41CD45RA1 (helper
naı¨ve T cells) subset recovery is delayed more than
a year, whereas CD81CD45RA1 (cytotoxic naı¨ve T
cells) normalize within the first month post-SCT.
There was a correlation with the donor age and speed
of recovery of CD41CD45RA1 T cells, with younger
age of the donor being significantly associated with
a faster recovery (r 5 .3; P 5 .032). Kaplan-Meier es-
timates showed that the median time for B cell (CD19)
reconstitution was 4 months (95% CI: 1-7 months).
There were too few and insignificant variations in im-
munosuppression withdrawal to comment on the
Table 2. Comparison of Graft Characteristics and Clinical Outcomes among Recipient’s of Marrow Obtained from Unprimed and
G-CSF Primed Bone Marrow
BM (n 5 37) G-BM (n 5 24)
Characteristics n(%), Median (Range) P-Value
TNC 108/kg 3.9 (1.7-22.7) 5.3 (1.7-10) .028
Graft characteristics
(cell 106/kg)
— — —
HSC CD34+ 7 (2.9-19.4) 7.5 (1.2-17.7) .647
HSC CD133+ 3.4 (1-14.2) 5.1 (0.5-10.8) .447
Natural killer CD56+16+CD32 3.4 (0.9-49.8) 5.8 (0.1-15.2) .039
Total B cell CD19+ 5.3 (0.3-52.5) 22.8 (0.1-118.4) .010
Total T cell CD3+ 45.6 (12.7-155.1) 41.2 (8.9-119.2) .425
Helper T cell CD4+ 22.2 (7.2-104.9) 23.2 (4.6-66.3) .941
Cytotoxic T cell CD8+ 21.5 (7-91) 21.3 (4.2-43.6) .194
Helper naı¨ve cell CD4+CD45RA+ 12.2 (2.4-61.5) 10.3 (0.9-53.5) .813
Cytotoxic naı¨ve cell CD8+CD45RA+ 14.2 (4.8-69.4) 10.4 (2.2-30.8) .029
Helper Memory cell CD4+CD45RO+ 6.9 (1.6-49.4) 8.9 (2.8-20.3) .061
Cytotoxic Memory cell CD8+CD45RO+ 6.0 (1.2-28.7) 7.3 (0.1-16.5) .871
MC CD11c+HLADR+Lin2 0.3 (0.1-4.1) 0.5 (0.1-2.5) .234
PC CD123+HLADR+Lin2 0.7 (0.1-2.8) 1.3 (0.2-5.1) .007
ANC >500/mm3 16 (10-23) 16 (14-20) .895
Platelet >20,000/mm3 28 (12-49) 26 (20-46) .763
Day 28 subsets (106/Lt) — — —
CD3 358 (47-1434) 177 (41-779) .120
CD19 9 (2-50) 6 (1-87) .130
CD4 167 (27-545) 97 (9-368) .179
CD8 254 (4-1134) 103 (24-528) .224
Natural killer 142 (27-1718) 136 (3-539) .749
MC 7 (1-50) 11 (1-38) .441
PC 5 (1-25) 8 (1-37) .523
Acute GVHD (grade II-IV) 5 (18) 2 (9) .444
Chronic GVHD 2 (9) 3 (14) .658
Survival
Secondary graft rejection 3 (8) 5 (21) .325
Death 10 (27) 4 (17) .534
EFS at 3 years 64% ± 8% 71 ± 9% .385
OS at 3 years 72% ± 8% 79 ± 10% .244
MC indicatesmonocytoid dendritic cells; PC, plasmacytoid dendritic cells; EFS, event-free survival; OS, overall survival; GVHD, graft-versus-host disease;
ANC, absolute neutrophil count; TNC, total nucleated cells; HSC, hematopoietic stem cell.
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The immune reconstitution data of this cohort is sum-
marized in Figures 1 and 2.
Factors Influencing Immune Reconstitution
Post-SCT
Stem cell source and conditioning regimen
The Kaplan-Meier estimates of NK, cytokine in-
duced killer cells (CIK2CD31CD561CD161), B and
T cells subsets (CD4, CD4D45RA, CD4CD45RO,
CD4CD25, CD8, CD8CD45RA, CD8CD45RO,
and CD8CD25), and plasmacytoid dendritic cells
recoverywere not significantly different between trans-
plants utilizing either a BM or G-BM graft source.
However, the AUC values of NK, B, T cell subsets
(except for CD8, CD8CD45RO, and CD8CD25),
and dendritic cells were all significantly higher in pa-
tients receiving G-BM compared with BM grafts, al-
though this did not translate into a significant
improvement inEFS,OS, or reduction in the incidence
of infections (Table 2). These graft sources also dif-
fered in reconstitution of monocytoid dendritic cells.
The day 30 Kaplan-Meier estimate for MC recoverywas 32% 6 10% and 18% 6 9% for BM and G-BM,
respectively (P 5 .029). There were no significant dif-
ferences in the immune reconstitution patterns among
patients who received antilymphocyte globulin (ALG)
as part of the conditioning regimen versus those who
did not (Table 3).
Acute GVHD
Patients with aGVHD grade (II-IV) had higher
CD3 (P 5 .012), CD8 (P 5 .002), CD8CD45RA
(P5 .027), and CD8CD45RO (P5 .005) AUC values
compared with those who did not develop GVHD.
Among cases that did develop grade II-IV GVHD
the absolute counts were significantly higher on day
15 in the following cellular subsets; CD8: 116 versus
52 cells/mL, P 5 .012, CD8CD45RA: 74 versus 19
cells/mL, P 5 .005, and CD8CD45RO: 44 versus 21
cells/mL, P5 .010. Only 1 of 8 patients who eventually
developed aGVHD had evidence of aGVHD at this
timepoint.
Infections
Patients who had evidence of viral infections post
transplant (within study time period of 1 year) had
Figure 1. Reconstitution kinetics of NK, B, T, and dendritic cell subsets in the first year post-SCT. Each line indicates corresponding cellular subsets at
appropriate time points post-SCT. Error bars indicate the 25th to 75th percentiles values. Median pretransplant values are shown as a horizontal bar and
the baseline error bars service as the reference range (highlighted area). MC, monocytoid dendritic cells; PC, plasmacytoid dendritic cells.
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.021) compared with those that did not. None of the
other cellular subsets AUC or absolute values at any
time point significantly differed in those who had
and those who did not develop a viral infection. Simi-
larly, there was no obvious correlation with cellular
subset recovery kinetics and bacterial, fungal, or viral
infections.
Impact of Graft Characteristics and Day 28
Lymphocyte Subset Counts on Clinical
Outcomes
After extensive immune reconstitution analysis
and its impact on clinical outcomes, the only timepoint where differences in cellular subset levels
had a significant impact on clinical outcome after
engraftment was the day 28 subset values. Eleven
of 63 patients were excluded for day 28 subset anal-
ysis. Nine died before day 28, whereas in 2 patients
a blood sample was not available at this particular
time point. Fifty-two patient’s values were available
for evaluation at this time point. The day 28 values
represent an early period of measurable donor im-
mune reconstitution and could also potentially be
a clinically useful early predictor for outcomes after
SCT. Hence, further detailed analysis of this time
point along with graft characteristics on clinical
outcomes was undertaken in this study.
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Figure 2. Overview of reconstitution kinetics of lymphocyte subsets and immune cells in the first year post-SCT. Each bar represents totalWBC count,
whereas lines indicate the corresponding cellular subsets at appropriate time points post-SCT (N 5 63). (A) Illustrates reconstitution of total T cells
(CD3), helperT cells (CD4), cytotoxicT cells (CD8), and natural killer (NK,CD32CD561CD161). Post-HSCTrecovery pattern of B cells (CD19), helper
naı¨ve T (CD4CD45RA), helper memory T (CD4CD45RO), cytotoxic naı¨ve T (CD8CD45RA), and cytotoxic memory T (CD8CD45RO) cells are shown
in (B), whereas cytokine-induced killer (CIK, CD31CD561CD161) and dendritic cell recovery for both monocytoid (MC, Lin2HLADR2CD11C1) and
plasmacytoid cells (PC, Lin2HLADR2CD1231) are depicted in (C).
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The median time to neutrophil and platelet en-
graftment was 16 days (range: 10-23) and 26 days
(range: 10-49), respectively. Patients with day 28 NK
above the median value (.142/mL) had faster platelet
engraftment compared with those below the median
value (26 versus 30 days, P 5 .031) (Table 4). None
of the other cellular subset had an impact on the
time to neutrophil and platelet engraftment. Fifteen
of 63 patients (24%) rejected their graft; 7 of 15 were
primary graft failures and were excluded from day 28
analysis. Among the 7 cases with primary graft failure
the median leukocyte counts on day 28 was 0.3  109/
Lt (range: 0.2-0.8). At this time point and at an earlier
(day 15) time point the leukocyte count was too low to
make a meaningful assessment of subset cellular im-
mune reconstitution. Of the remaining 8 patients, 2
(13%) had early and 6 (40%) had late secondary graft
rejections post-SCT. After excluding primary graft
failures (n 5 7), the median day 28 NK count in pa-
tients who rejected their graft (n5 8) was significantly
lower compared to those who did not reject (n 5 42)
(91/mL versus 150/mL; P5 .013) as shown in Figure 3.None of the other cellular subsets at this time point
was significantly associated with graft rejection. There
was no evidence that graft rejection was preceded
or directly related to any infective process. Posttrans-
plant chimerism at day 28 was complete in 37 of 52
patients (71%) with only donor-specific bands. Among
the patients with mixed chimera (15/52 5 29%),
the donor band contributed a median of 87% (range:
26-98).
GVHD
Eight of 52 (15%) patients who could be evalu-
ated developed aGVHD grade (II-IV). Five of 45 pa-
tients (11%) surviving .100 days developed
cGVHD. None of the subsets that were found to
be a risk factor in univariate analysis retained signifi-
cance for aGVHD (CD4CD45RO and CD4CD25
cell dose) and cGVHD (CD34 cell dose, day 28 acti-
vated NK and day 28 CD8CD25 cells) in a multivar-
iate analysis. There was no association of day 28
dendritic cells with development of GVHD. Simi-
larly, neither the graft source (BM or G-BM) or the
use of ALG in the conditioning regimen had an
Table 3. Comparison of Graft Characteristics and Clinical Outcomes among Recipient’s Who Received Antilymphocyte Globulin
in Their Conditioning Regimen versus Those Who Did Not
ATG/ALG (n 5 37)
Without ATG/ALG
(n 5 26)
Characteristics n(%), median (range) P-Value
TNC 108/kg 4.8 (1.7-10) 3.9 (1.7-22.7) .276
Graft characteristics (cell 106/kg) — — —
HSC CD34+ 7.1 (1.2-17.7) 7.6 (2.9-23) .660
HSC CD133+ 3.9 (0.5-10.8) 3.8 (1-16.6) .785
Natural killer CD56+16+CD32 5.6 (0.1-49.8) 3.4 (1.1-23.3) .054
Total B cell CD19+ 21.6 (0.1-118.4) 3.5 (0.3-52.5) .001
Total T cell CD3+ 41.7 (8.9-120.1) 47.1 (24-202) .125
Helper T cell CD4+ 22.5 (4.6-66.3) 22.8 (11-113.7) .295
Cytotoxic T cell CD8+ 21.9 (4.2-91) 21.9 (14.4-104.6) .204
Helper naı¨ve cell CD4+CD45RA+ 10.2 (0.9-53.5) 10.3 (2.4-66.3) .577
Cytotoxic naı¨ve cell CD8+CD45RA+ 12.4 (2.2-50.1) 13 (7.4-69.4) .204
Helper memory cell CD4+CD45RO+ 8.8 (1.6-28.3) 7.2 (3.3-66.5) .219
Cytotoxic memory cell CD8+CD45RO+ 6.7 (0.1-28.7) 7.4 (1.2-43.9) .577
MC CD11c+HLADR+Lin2 0.5 (0.1-4.1) 0.3 (0.1-0.8) .009
PC CD123+HLADR+Lin2 1.3 (0.2-5.1) 0.7 (0.1-2.8) .003
ANC >500/mm3 16 (10-20) 17 (13-23) .155
Platelet >20,000/mm3 28 (18-46) 26 (10-49) .123
Day 28 subsets (106/Lt) — — —
CD3 224 (41-1230) 486 (47-1434) .065
CD19 8 (1-87) 10 (3-39) .256
CD4 116 (9-388) 155 (27-545) .281
CD8 140 (14-967) 313 (4-1134) .091
Natural killer 141 (3-539) 142 (27-1718) .788
MC 11 (1-38) 6 (1-50) .514
PC 8 (1-37) 5 (1-25) .497
Acute GVHD (grade II-IV) 4 (12) 4 (21) .443
Chronic GVHD 4 (13) 1 (8) 1.000
Survival
Secondary graft rejection 6 (16) 2 (8) .448
Death 6 (16) 8 (31) .223
EFS at 3 years 76% ± 3% 60% ± 10% .145
OS at 3 years 86% ± 5% 63% ± 10% .066
MC indicates monocytoid dendritic cells; PC, plasmacytoid dendritic cells; EFS, event-free survival; OS, overall survival; GVHD, graft-versus-host
disease; ANC, absolute neutrophil count; TNC, total nucleated cells; HSC, hematopoietic stem cell; ATG, antithymocyte globulin; ALG, antilymphocyte
globulin.
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(Tables 2 and 3).
Infections
During the posttransplant study period 22% of
patients had documented bacterial, 13% had viral,
and 11% had fungal infections (proved, possible, and
probable), which were microbiologically or clinically
documented. Patients who received a higher than
median CD34 cell dose (median 5 7.3  106/kg) had
lower incidence of bacterial (P 5 .003) and fungal
infections (P 5 .005), whereas viral infections were
not influenced by stem cell dose. The median time to
neutrophil engraftment was not different between
these groups (17 versus 16 days, P5 .53). The protec-
tive effect of increasing CD34 cell dose was retained in
a multivariate analysis (hazard rato [HR] 5 0.3, P 5
.044) after adjusting for factors that had significance
in univariate analysis such as patient age, high-risk
group (age $7 and liver size $cm), and NK cell
dose. Neither the graft source (BM versus G-BM) orthe use of ALG in the conditioning regimen had an
effect on post SCT infections.
Survival
The 3-year Kaplan-Meier estimate of EFS and OS
was 67%6 6% and 78%6 5%, respectively, at a mean
follow-up of 37 months. Eleven of 63 patients (18%)
died of TRM within day 100. Among the 11, 8
(73%) deaths were because of RRT, whereas 3 (27%)
died of primary graft failure and secondary infections.
None of the cellular subsets, either in the graft or those
that reconstituted by day 28 influenced the day 100
TRM. However, the day 28 NK counts were found
to be statistically significantly associated with EFS
andOSwhen analyzed as continuous variables in a uni-
variate analysis (P 5 .013 and .034, respectively).
There was no significant difference in the OS and
EFS between BM and G-BM stem cell source. Simi-
larly, there was no correlation with OS and EFS
among those receiving ALG versus those that did not
(Tables 2 and 3).
Table 4. Comparison of Low and High Day 28 NK Cell Count Patient Groups
Day 28 NK n (%)/Median (Range)
Characteristics Low (#142/mL) n 5 26 High (>142/mL) n 5 26 P-Value
Patient — — —
Age (years) 7 (2-14) 8 (2-13) .904
Males 15 (58) 16 (62) 1.000
Sex mismatch transplant 10 (39) 9 (35) 1.000
Lucarelli class III 14 (54) 11 (42) .579
Splenectomy 2 (8) — .490
High risk 3 (12) 2 (8) 1.000
TNC (108/kg) 4.2 (1.7-10) 4.6 (1.7-22.7) .442
Graft (106/kg) — — —
CD34 6.7 (1.2-16.9) 8.5 (1.8-23) .231
CD133 3.8 (1.1-10.8) 4.4 (0.5-16.6) .191
CD3 43.4 (8.9-132) 41.7 (20.8–202) .534
CD19 5.1 (0.1-118.4) 18.4 (0.7-61.6) .044
CD4 22.1 (4.6-66.3) 24.7 (8.7-113.7) .360
CD8 21.5 (4.2-63) 21.1 (9.5-104.6) .297
NK 4.2 (0.1-15.2) 6.4 (1.1-23.3) .076
MC 0.3 (0.1-1.1) 0.6 (0.1-4.1) .023
PC 0.8 (0.1-5.1) 1.3 (0.2-4) .164
Engraftment (days) — — —
ANC >500/mm3 17 (11-23) 16 (13-20) .358
Platelet >20,000/mm3 30 (15-49) 26 (10-42) .031
Day 28 subsets (106/Lt) — — —
CD3 155.4 (40.5-1210.9) 232.1 (142.1-1718.1) .002
CD19 7.5 (0.6-86.6) 12.5 (0.8- 42.4) .089
CD4 78.9 (8.9-433.4) 200.6 (48.6- 544.5) .000
CD8 75.2 (3.7-1041) 269.3 (85.5-1134) .002
MC 5.5 (0.3-50) 11.4 (1.3-38) .027
PC 6 (0.1-18.9) 9.1 (0.7-37.2) .070
Acute GVHD (grade II-IV) 3 (12) 4 (15) 1.000
Chronic GVHD 2 (9) 3 (13) 1.000
Survival — — —
Secondary graft rejection 7 (35) 1 (4) .021
Death 5 (19) — .051
EFS at 3 years 64% ± 10% 96% ± 4% .006
OS at 3 years 70% ± 14% 100% ± 0% .017
MC indicatesmonocytoid dendritic cells; PC, plasmacytoid dendritic cells; EFS, event-free survival; OS, overall survival; GVHD, graft-versus-host disease;
ANC, absolute neutrophil count; TNC, total nucleated cells; NK, natural killer.
Biol Blood Marrow Transplant 15:597-609, 2009 605Cellular IR on Children with b Thalassemia MajorImpact of Day 28 NK Counts on Clinical
Outcomes
The day 28 NK counts were found to be statisti-
cally significantly associated with secondary graft re-
jection, EFS, and OS when analyzed as continuous
variables in univariate analysis (P 5 .044, .013, .034,
respectively). None of the other lymphocyte subsets
that reconstituted post-SCT at this timepoint had an
impact on these clinical outcomes. Hence, a further
detailed analysis was done based on the day 28 NK
cell count. The median day 28 NK cell count for those
who could be evaluated (52 patients) was 142 cells/mL
(range: 3-718 cells/mL).
Patients were grouped based on median value for
day 28 NK cells (#142/mL) as low and the rest as
high group (.142/mL) to calculate relative risk for
transplantation outcomes. The low and high day 28
NK (N 5 26 each) groups were comparable with re-
gard to age, sex mismatch transplants, lucarelli class
III, high risk class III, conditioning regimen, GVHD
prophylaxis regimen, and graft characteristics (CD34,
CD133, CD3, CD4, CD8, andNK cell dose) as shownin Table 4. However, the CD19, monocytoid cells
(MC) in the graft and engraftment kinetics of CD3,
CD4, CD8, and MC cells were significantly different
between the 2 groups (Table 4).
Rejection
The factors that influenced graft rejection in uni-
variate analysis was low day 28 NK #142/mL (HR 5
8.2, 95% CI: 1.0-66.7, P 5 .049) and splenectomy
(HR 5 46.5, 95% CI: 2.9-743, P 5 .007). Because
only 2 patients had splenectomy, this variable was ex-
cluded for multivariate analysis. On a multivariate
analysis adjusting for patient age, sex mismatch trans-
plant, Lucarelli class, high-risk class III (age $ and
liver size $5 cm), conditioning regimen, and graft
sources only a low day 28 NK (#142/mL) retained sta-
tistical significance for rejection (HR5 11.1, 95% CI:
1.14-106.81, P 5 .038) (Table 5).
Cumulative incidence of rejection compared by
log rank test revealed that the lowNK group had a sig-
nificant risk for secondary graft rejections (P 5 .019)
(Figure 4). The sensitivity and specificity for low day
Figure 3. Median day 28 NK cell counts and secondary graft rejection.
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and 60%, respectively.
GVHD
There was no association of day 28 NK cells with
regard to development of aGVHD and cGVHD
(P 5 .620 and .736, respectively).
Survival
On a multivariate analysis with standard risk fac-
tors such as patient age, sex mismatch transplant, Lu-
carelli class, high risk class III (aged$7 years and liver
size $5 cm), conditioning regimen and graft sources,
only a low day 28 NK (#142/mL) retained statistical
significance for EFS (HR 5 16.3, 95% CI: 1.6-161,
P 5 .017) along with patient’s age (HR 5 0.7, 95%
CI: 0.6-1, p 5 .034). Survival curve analysis also
showed that a low day 28 NK cell count (\142/mL)
was a risk factor for EFS (P 5 0.006) and OS (P 5
.017) as illustrated in Figure 4.DISCUSSION
The factors that influenced immune reconstitution
in our analysis was similar to those that have been re-
ported previously [28-30]. Our analysis was consistent
with previously reported data in which NK cells were
noted to recover to normal levels within 1 to 2 monthsTable 5. Multivariate Relative Risk Analysis for Secondary
Graft Rejection
Variable HR (95% CI) P-Value
Patient age 0.1 (0.79-1.00) .108
Sex mismatch transplant 1.8 (0.44-7.57) .652
Graft source 0.6 (0.06-6.72) .713
Conditioning regimen 1.3 (0.09-18.18) .842
Lucarelli Class III 3.2 (0.48-20.74) .233
High risk
(age $7 years and liver size $5 cm) [21]
3.1 (0.23-43.16) .396
Day 28 NK low #142/mL 11.1 (1.14-106.81) .038
HR indicates hazard ratio; CI, confidence interval.following SCT, and remained the predominant lym-
phoid subset in the peripheral blood regardless of
transplant type, stem cell source and quantity, patient
age, and occurrence of GVHD [1]. Similarly, consis-
tent with reports in the literature, CD81 levels recov-
ered rapidly as their reconstitution is possibly favored
by extra thymic origin, whereas CD41 subset recovery
(thymic dependent) is impaired [8]. CD45RO1T cells
are memory cells, which respond in vitro to recall an-
tigens, whereas CD45RA1 T cells are naı¨ve cells, re-
cently issued from the thymus. It has been reported
that children have faster recovery of CD45RA1T cells
than adults because of the potential for thymic re-
bound posttransplantation, and this in turn, could con-
tribute to the reduced risk of infections in children in
the posttransplant period [2,31,32]. In this study re-
covery of CD41CD45RA1 naı¨ve T cells was slow,
consistent with the pace of recovery that has been re-
ported in the literature [1], and remained below nor-
mal levels for the period of this study (1 year),
whereas CD81CD45RA1 naı¨ve cells normalize within
the first month posttransplant. Previous reports had
suggested that the younger the donor age the faster
the recovery of CD41 CD45RA1 T cells [31]. In this
analysis we have also noted a similar correlation be-
tween donor age and CD41CD45RA1 T cell recov-
ery, with transplants involving younger donors
having a faster recovery of this subset (r 5 .3, P 5
.032). Although we did notice a decreased risk for bac-
terial and fungal infections among patients who re-
ceived a higher stem cell dose, we could not correlate
this to faster CD41CD45RA1 T cell recovery (data
not shown).
Both dendritic subsets, namely, monocytoid and
plasmacytoid cells, in our analysis recovered within
a month following transplant, which is consistent
with a previously reported data [33]. We and others
have reported that in the setting of a peripheral blood
SCT a low day 28 plasmacytoid dendritic cell count
was associated with aGVHD and cGVHD [3,4]. In
this study we were unable to demonstrate a similar ef-
fect. This could be because of the small numbers that
actually developed GVHD, or it could be that low
day 28 plasmacytoid DC count is not predictive of
GVHD when the graft source is bone marrow. Larger
studies will be required to clarify this further.
Data from this analysis suggests that in this cohort
of patients, increasing the stem cell dose reduces the
risk of posttransplant bacterial and fungal infections.
We hypothesize that faster immunologic recovery oc-
curs with higher CD34 cell doses, and consequently,
diminishes the risk of bacterial and fungal infections
as observed in a previous report [34]. However, we
were not able to demonstrate a correlation in speed
of recovery of any specific cellular subset in relation-
ship to the stem cell dose. We also noted that patients
in the highest quartile of the stem cell dose did not
Figure 4. Kaplan-Meier estimates of graft rejection, EFS, andOS by day
28 NK cell groups. (A) Secondary graft rejection. (B) EFS.
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not shown). Although the number of events is few
and the cohort studied small, it would still be reason-
able in future to target a CD34 cell dose of 10 
106/kg or an MNC dose of 6  108/kg in the graft(lower limit of the fourth quartile values of graft cell
dose) in these patients. At these doses, our data would
suggest that there should be a significant reduction in
posttransplant bacterial and fungal infections without
an increased risk of GVHD.
Studies in major histocompatibility complex
(MHC) mismatched transplants done in mice and
humans have shown that donor NK cells target
hematopoietic tissues of the host, eliminating host
antigen-presenting cells (APCs) and exerting a GVL
effect against leukemia [35]. A similar effect has been
noted with the NK cell dose in the allograft, a higher
dose of NK cell infusion being associated with a lower
risk of GVHD even in matched sibling transplants
[36]. Savani et al [13] have demonstrated that rapid
NK cell recovery (NK .150/mL around day 30) as
an independent determinant predicting less relapse
and better survival after T cell-depleted matched
SCT in patients with myeloid malignancies. Previ-
ously, the same group had shown that the day 30 NK
cell count was a surrogate marker for rapid molecular
remission in CML patients [37]. Matthes-Martin et al
[38] highlighted the role of NK cells during the early
posttransplant period. This group has showed a strong
correlation of secondary graft rejection and detection
of recipient NK cells on day 28. Our observations in
this cohort of patients are consistent with some of
the above reports.
Among the lymphocyte subsets at day 28, a promi-
nent role for NK cell reconstitution was noted. Our
data suggests for the first time that the absolute num-
bers of NK cells after allogeneic SCT for patients with
b thalassemia major is a strong predictor of secondary
rejection and EFS. We have noted that patients who
had less than the median number of NK cells on day
28 had a higher incidence of rejection and an inferior
EFS and OS. It is important to emphasize that our
low and high day 28 NK patient groups (n 5 26
each) were comparable with regard to recipient age,
sex mismatch transplants, lucarelli Class III, and graft
characteristics (CD34, CD133, CD3, CD4, CD8, and
NK cell dose). However, there were differences be-
tween these 2 groups for the CD19 and monocytoid
dendritic cell (MC) dose in the graft, and there were
significant differences in the engraftment kinetics of
CD3, CD4, CD8, and MC cells between the 2 groups;
none of these differences except for a low day 28 NK
cell count was associated with rejection in a multivari-
ate analysis. Among patients who had a secondary graft
rejection we attempted but failed to demonstrate a sub-
set cellular immune reconstitution parameter beyond
day 28, which could predict eventual graft rejection.
A limitation of this study was that in the patients
who did reject their grafts we did not have cellular sub-
set chimerism data. Twenty-five of our patients were
treated with a new Flu-based conditioning regimen
that could have had an impact on rejection rates. On
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ation in conditioning regimen low day 28 NK cell
count was significantly associated with secondary graft
rejection. On subset analysis a low day 28 NK cell
count was significantly associated with reduced EFS
and OS in patients who received either of these condi-
tioning regimens (data not shown). Also, neither con-
ditioning regimens were independently associated
with secondary graft rejection (P 5 .69).
Identifying potential causes of low peripheral
blood day 28 NK counts after SCT among those
who reject their graft needs further investigation. We
could not find any association between graft character-
istics and the day 28 NK cell count nor could we iden-
tify any predictors of a low day 28 NK cell count.
Conventional risk stratification for patients with
b thalassemia major is based on presence of hepato-
megaly, evidence of portal fibrosis in the liver, and in-
adequate iron chelation therapy (Lucarelli class I, II,
and III) [20]. This classification has been validated by
different groups, and remains the most important
prognosticator for patients with b thalassemia major
undergoing an allogeneic SCT. In our study, besides
the lucarelli class III status at transplantation the only
other factor significantly affecting clinical outcome
was the day 28 NK cell count. The day 28 NK cell
count was noted to be independent of the Lucarelli
risk stratification and would serve to complement it
as a posttransplant parameter to stratify patient’s
risk of secondary rejection. Whether interventions
based on the day 28 NK cell count would alter the re-
jection rates remains to be validated in prospective
clinical trials.
In summary, this analysis confirms that immune
recovery posttransplant in pediatric patients with
b thalassaemia major under going a matched related
myeloablative allogeneic SCT follows similar recovery
kinetics as observed previously with different hemato-
logic disorders [39]. The present study on graft and
immune reconstitution characteristics has also helped
better define the optimal stem cell dose that one should
target, and could not find any clinically significant ad-
vantage of using G-CSF primed BM as a stem cell
source. The results also suggest that a low day 28
NK cell count increases the risk for secondary graft re-
jection and might predict death in patients with b thal-
assaemia major undergoing a myeloablative matched-
related allogeneic SCT. The day 28 NK cell count,
a technically easy, highly reproducible and inexpensive
assay, could serve as an important posttransplant prog-
nosticator for these patients.ACKNOWLEDGMENTS
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